Geron Corp. diskutieren
Geron Corp.
WKN: 902213 / Symbol: GERN / Name: Geron / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
3,91 €
1,88 %
Sell Geron Corp.
Geron Co. (NASDAQ: GERN) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $6.00 price target on the stock.
Ratings data for GERN provided by MarketBeat
Geron Co. (NASDAQ: GERN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $4.00 price target on the stock.
Ratings data for GERN provided by MarketBeat
Geron Co. (NASDAQ: GERN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $4.00 price target on the stock.
Ratings data for GERN provided by MarketBeat
Geron Co. (NASDAQ: GERN) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $6.00 price target on the stock.
Ratings data for GERN provided by MarketBeat
Geron Co. (NASDAQ: GERN) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating. They now have a $4.00 price target on the stock.
Ratings data for GERN provided by MarketBeat
Geron Co. (NASDAQ: GERN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $4.00 price target on the stock.
Ratings data for GERN provided by MarketBeat
Geron Co. (NASDAQ: GERN) had its price target raised by analysts at Needham & Company LLC from $4.00 to $5.00. They now have a "buy" rating on the stock.
Ratings data for GERN provided by MarketBeat
Geron Co. (NASDAQ: GERN) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $4.00 to $5.00. They now have a "buy" rating on the stock.
Ratings data for GERN provided by MarketBeat
Geron Co. (NASDAQ: GERN) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $6.00 price target on the stock.
Ratings data for GERN provided by MarketBeat
Geron Co. (NASDAQ: GERN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $5.00 price target on the stock.
Ratings data for GERN provided by MarketBeat
Geron Co. (NASDAQ: GERN) is now covered by analysts at TD Cowen. They set a "buy" rating and a $10.00 price target on the stock.
Ratings data for GERN provided by MarketBeat
Geron Co. (NASDAQ: GERN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $5.00 price target on the stock.
Ratings data for GERN provided by MarketBeat
Geron Co. (NASDAQ: GERN) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $7.00 price target on the stock.
Ratings data for GERN provided by MarketBeat
Geron Co. (NASDAQ: GERN) had its price target raised by analysts at Needham & Company LLC from $5.00 to $6.00. They now have a "buy" rating on the stock.
Ratings data for GERN provided by MarketBeat
Geron Co. (NASDAQ: GERN) had its price target raised by analysts at Stifel Nicolaus from $6.00 to $7.00. They now have a "buy" rating on the stock.
Ratings data for GERN provided by MarketBeat
Geron Co. (NASDAQ: GERN) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $9.00 price target on the stock.
Ratings data for GERN provided by MarketBeat
Geron Co. (NASDAQ: GERN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $6.00 price target on the stock.
Ratings data for GERN provided by MarketBeat
Geron Co. (NASDAQ: GERN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $6.00 price target on the stock.
Ratings data for GERN provided by MarketBeat
Geron Co. (NASDAQ: GERN) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $7.00 price target on the stock.
Ratings data for GERN provided by MarketBeat
Neueste Beiträge
Cantor_Fitzgerald in Insmed Inc. diskutieren